## PATENT COOPERATION TREATY

# **PCT**

# **INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
MXL/PB60607	ACTION a	s well as, where applicable, item 5 below.
International application No.	International filing date (day/month/yea	(Earliest) Priority Date (day/month/year)
PCT/GB2004/005343	20/12/2004	22/12/2003
Applicant		
GLAXO GROUP LIMITED		
	is been prepared by this international Searching transmitted to the international Bureau.	g Authority and is transmitted to the applicant
This International Search Report co	nsists of a total of7 sheets.	
X It is also accompan	ied by a copy of each prior art document cited I	n this report.
Basis of the report	<del></del> `	
	e, the international search was carried out on t ed, unless otherwise indicated under this item.	ne basis of the international application in the
	tional search was carried out on the basis of a ty (Rule 23.1(b)).	translation of the international application furnished to
b. X With regard to any	nucleotide and/or amino acid sequence disc	losed in the international application, see Box No. I.
2. X Certain claims we	re found unsearchable (See Box II).	
3. Unity of invention	is lacking (see Box III).	
4. With regard to the title,		
the text is approved	as submitted by the applicant.	
lippood .	stablished by this Authority to read as follows:	
NOGOA ANTIBODIES F	OR THE TREATMENT OF ALZHEIME	IR DISEASE
5. With regard to the abstract,		
X the text is approved	as submitted by the applicant.	
Land I		uthority as it appears in Box No. IV. The applicant I search report, submit comments to this Authority.
6. With regard to the drawings,		
a. the figure of the drawings t	to be published with the abstract is Figure No	<del></del>
as suggest	ed by the applicant.	
as selected	by this Authority, because the applicant failed	to suggest a figure.
	by this Authority, because this figure better ch	aracterizes the invention.
b. X none of the figures	is to be published with the abstract.	

International application No.

### **INTERNATIONAL SEARCH REPORT**

PCT/GB2004/005343

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With Inver	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed atton, the international search was carried out on the basis of:
	a.	type of material  X a sequence listing table(s) related to the sequence listing
	b.	format of material  X in written format  in computer readable form
	c.	contained in the international application as filed filed together with the international application in computer readable form  turnished subsequently to this Authority for the purpose of search
2.	х	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or turnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addit	tional comments:

#### INTERNATIONAL SEARCH REPORT

International Application No PCT/GB2004/005343

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/22 A61P25/28 C12N05/08

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/088926 A (PHARMACIA & UPJOHN COMPANY; YAN, RIQIANG; LU, YIFENG) 30 October 2003 (2003-10-30) cited in the application page 4, line 5 - page 5, line 8 page 17, lines 15-18 claims 43-45	16
<b>X</b>	WO 02/058323 A (GLAXO GROUP LIMITED; SMITHKLINE BEECHAM PLC; BLACKSTOCK, WALTER, PHILI) 25 July 2002 (2002-07-25) cited in the application page 2, lines 8-27 page 14, lines 14-26 page 15, lines 28-31 page 16, lines 6-18 examples 5,6	1-6

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
<ul> <li>Special categories of cited documents:</li> <li>'A' document defining the general state of the art which is not considered to be of particular relevance</li> <li>'E' earlier document but published on or after the international filing date</li> <li>'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>'O' document referring to an oral disclosure, use, exhibition or other means</li> <li>'P' document published prior to the international filing date but later than the priority date claimed</li> </ul>	<ul> <li>'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>'&amp;' document member of the same patent family</li> </ul>
Date of the actual completion of the international search  3 June 2005	Date of mailing of the international search report  10/06/2005
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5816 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Noë, V

3

## **INTERNATIONAL SEARCH REPORT**

International Application No
PCT/GB2004/005343

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Refevent to claim No.
X	WO 00/31235 A (SCHWAB, MARTIN, E; CHEN, MAIO, S) 2 June 2000 (2000-06-02)  page 4, lines 12-21 page 11, lines 3,4 page 11, line 33 page 28, line 1 - page 29, line 32 page 42, line 20 - page 43, line 25 page 59, lines 1-10	7,10, 12-14, 18,19
X	STRITTMATTER S M: "MODULATION OF AXONAL REGENERATION IN NEURODEGENERATIVE DISEASE FOCUS ON NOGO"  JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 19, no. 1/2, August 2002 (2002-08), pages 117-121, XP009029170 ISSN: 0895-8696 the whole document	7,10-13, 19
A	US 2003/113891 A1 (BLATT LAWRENCE ET AL) 19 June 2003 (2003-06-19) the whole document	
P,X	WO 2004/052932 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; UNIVERSITAET ZUERICH; BARSKE, CARME) 24 June 2004 (2004-06-24) abstract page 18, last paragraph examples 3,4	7,10, 12-14, 18,19
P,X	WO 2004/093893 A (STRITTMATTER, STEPHEN, M; LEE, DANIEL, H., S; LI, WEIWEI) 4 November 2004 (2004-11-04) cited in the application paragraphs '0004!, '0005!, '0010!, '0014!, '0021!, '0029!, '0069!, '0070!	1-19
E	WO 2005/028508 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; UNIVERSITY OF ZURICH; BARSKE, CARME) 31 March 2005 (2005-03-31) abstract page 2, last paragraph page 20, last paragraph	7-13,18,

3

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

#### Continuation of Box II.1

Although claims 1-6 (insofar directed to in vivo methods) and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

#### Continuation of Box II.2

Present claims 1-5,7-12 relate to a methods and uses of a product defined by reference to a desirable characteristic or property, namely a Nogo antagonist. The claims cover methods and uses of all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to methods or uses of function blocking monoclonal NogoA antibodies (see examples).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

International application No. PCT/GB2004/005343

# INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. χ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
Although claims 1-6 (insofar directed to in vivo methods) and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.	
Claims Nos.: because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
see FURTHER INFORMATION sheet PCT/ISA/210	
3. Claims Nos.:	
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest  The additional search fees were accompanied by the applicant's protest.	
No protest accompanied the payment of additional search fees.	

## **INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No
PCT/GB2004/005343

	atent document d in search report		Publication date		Patent family member(s)		Publication date
M۷	03088926	A	30-10-2003	AU	2003223330	Δ1	03-11-2003
MO	03000320	-	30-10-2003				30-10-2003
				CA	2482589		
				MO	03088926		30-10-2003
				US 	2004063161		01-04-2004
WO	02058323	A	25-07-2002	EP	1352084	A2	15-10-2003
				WO	02058323	A2	25-07-2002
				JP	2004531697		14-10-2004
				US	2004146953		29-07-2004
WO.	0031235	Α	02-06-2000	AU	774367	R2	24-06-2004
***	~~~*	• 1	02 00 2000	AU	1469200		13-06-2000
				BR	9915137		08-06-2004
				CA	2350395		02-06-2000
				CN	1354755		19-06-2002
				CZ	20011608		17-10-2001
				EP	1124846		22-08-2001
				ΗU	0301829		28-08-2003
				JP	2003531566	T	28-10-2003
				MΧ	PA01004598	Α	24-04-2002
				NO	20012223	Α	02-07-2001
				NZ	511683	Α	25-06-2004
				PL	362990		15-11-2004
				SK	6222001		03-12-2001
				WÔ	0031235		02-06-2000
				ZA	200103714		25-06-2004
	2003113891	A1	19-06-2003	US	2003060611	 Δ1	27-03-2003
JJ	F449113031	* 1.4	17 00 2000	EP	1386004		04-02-2004
				WO	02081628		17-10-2002
				U\$	2003203870		30-10-2003
				AU	3811101		20-08-2001
				CA	2398282		16-08-2001
				EP	1265995		18-12-2002
				JP	2003525037		26-08-2003
				MO	0159103	A2	16-08-2001
WO	2004052932	A	24-06-2004	AU	2003289998	A1	30-06-2004
				MO	2004052932	A2	24-06-2004
WO	2004093893	A	04-11-2004	MO	2004093893		04-11-2004
<u></u> -	2005028508	Δ	31_03_2005	WO	2005028508	Δ2	31-03-2005